Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

Lung Inflammation Clinical Trial

Official title: Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone

Status Completed

Clinical Trial Summary

The purpose of this research study is to gain understanding of the basic responses of the lung to inflammation and specifically if a certain medication can reduce the inflammation alone or in combination with another. Inflammation is the way our bodies react to irritation or injury, and involves red, warm, and often painful swelling of the affected tissue. "Acute lung injury" involves inflammation that is not specific to one area of the lung and is caused by any one of several conditions: infection, trauma, breathing toxic substances, etc. When lung injury is severe, not enough oxygen can get into the body; this can lead to the need for mechanical support of breathing (mechanical ventilation), problems with brain, heart or other organ function, and in some cases, death.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Alveolitis, Extrinsic Allergic
• Inflammation
• Lung Inflammation
• Pneumonia

• NCT number: NCT01174056
• Study type: Interventional
• Source: Washington University School of Medicine
• Status: Completed
• Phase: Phase 0
• Start date: July 2011
• Completion date: March 2014